PCSK9 inhibitors are recommended in very-high-risk patients with FH if the treatment goals are not reached on maximal doses of statins and ezetimibe therapy or in patients who cannot tolerate statins [7,87,88,89,90]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.